Business Wire

ExaGrid Announces New Features for MSPs in Version 7.4.0 Release

16.10.2025 14:00:00 CEST | Business Wire | Press Release

Share

ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that the ExaGrid Version 7.4.0 release, shipping in October 2025, includes new features optimal for Managed Service Providers (MSPs) who use ExaGrid Tiered Backup Storage to protect their customers’ data.

Many organizations use MSPs to outsource either a single IT function, such as Backup as a Service (BaaS) and Disaster Recovery as a Service (DRaaS), or even an entire data center, including all applications, servers, and storage. A number of MSPs already use ExaGrid Tiered Backup Storage, and ExaGrid’s new features will help MSPs track their customers’ data usage and separately provide the ability to restore an individual customer’s data in the case of a ransomware attack.

MSPs Can Store Multiple Customers in a Single ExaGrid System

  • Set up a specific share per customer (35 per appliance/300 per system – can have unlimited systems)
  • Data is tracked per share and reported for billing per TB/PB per customer
  • Report on backup data usage per share/customer both over time and via exported reports
  • To add a customer simply add a share, to eliminate a customer simply delete the share
  • Backups are fast due to a unique front-end disk cache Landing Zone
  • Backup windows stay fixed-length as data grows due to a true scale-out architecture
  • Restores are fast as the most recent data in the Landing Zone is undeduplicated
  • Cost is lower than standard storage due to advanced deduplication
  • A non-network facing Repository Tier (tiered air gap), Auto Detect & Guard, Delayed Delete Policy and immutable data objects ensure data can be restored after a ransomware attack
  • Ransomware recovery can happen on the share level as to not impact other customers

MSPs can use ExaGrid with over 25 backup applications including Veeam, Rubrik, Commvault, NetBackup, HYCU, Cohesity (in 2026), Oracle RMAN Direct, SQL Dumps Direct and many others.

ExaGrid provides MSPs with the same unique values it offers to other end users, including fast backups, fast restores, low capital equipment costs, a pay-as-you-grow model, comprehensive security, high-quality maintenance and support with predictable costs, strong technical support, and products that just work.

ExaGrid also recently announced that Version 7.4.0 also includes the release of ExaGrid’s AI-Powered Retention Time-Lock feature: Auto Detect & Guardfor all data center customers and also MSPs. Auto Detect & Guard uses AI to monitor all daily operational deletes on a per-share/customer basis, trains/learns, and creates patterns. If a delete request is outside of the pattern, the organization’s IT team is alerted and ExaGrid automatically extends the delayed delete policy for all shares/customers so data in the ExaGrid Repository Tier is never deleted. If the delete was an operational delete, the IT team can clear the alert and ExaGrid will return to the original delayed delete policy.

“ExaGrid is committed to helping MSPs meet their SLAs for their BaaS, DRaaS, and IT outsourced data center customers with our industry-leading backup storage that provides faster backup ingest performance, fast restores, comprehensive security and ransomware recovery, with unmatched reliability,” said Bill Andrews, President and CEO of ExaGrid. “With this new release, we are pleased to offer tracking by share and our AI-Powered Retention Time-Lock for Ransomware Recovery by the share/customer. MSPs that use ExaGrid can feel confident that their customer data is well-protected and always ready for recovery.”

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, scale-out architecture, and comprehensive security features, including AI-Powered Retention Time-Lock to recover from a ransomware attack ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and planned product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier (tiered air gap), delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Austria, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251016805979/en/

Contacts

Media Contact:
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye